Virtual Challenging Case Clinic: B-Cell Lymphomas

  • Delve into treatment paradigms, available therapies, and agents under development for various subtypes of B-cell lymphomas
  • Expert insights on particularly challenging patient cases submitted by actual attendees

john leonard

Course Director

John P. Leonard, MD
Senior Associate Dean for
Innovation and Initiatives
Executive Vice Chair,
Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology & Medical Oncology
Weill Cornell Medical College
New York, New York

Agenda

  • Welcome, Introductions, and
    Pre-session Survey
  • General Disease State and
    Treatment Guidelines
  • Expert Insights: Faculty-submitted cases
  • Case Presentation, Polling Questions,
    and Discussion
  • Q&A
  • Conclusion and Post-session Survey

Upcoming Webinars

April 14, 2021

Mantle Cell Lymphoma

Jonathon Cohen, MD, MS
Winship Cancer Center of Emory University | Atlanta, Georgia

May 12, 2021

CAR T-cell Therapy

Mehdi Hamadani, MD
Medical College of Wisconsin | Milwaukee, Wisconsin

June 9, 2021

Hodgkin’s Lymphoma

Ann LaCasce, MD
Dana-Farber Cancer Institute | Boston, Massachusetts

July 14, 2021

US National Clinical Trial Update Roundtable

John P. Leonard, MD
Weill Cornell Medicine, New York, New York
Brad Kahl, MD
Washington University School of Medicine, Saint Louis, Missouri
Jonathan Friedberg MD, MMSc
University of Rochester Medical Center, Rochester, New York

August 11, 2021

Updates from ASCO, EHA, and ICML

Gilles Salles, MD, PhD 
Memorial Sloan Kettering Cancer Center, New York, New York

September 8, 2021

Primary CNS Lymphoma

James Rubenstein, MD
UCSF Comprehensive Cancer Center, San Francisco, California

October 13, 2021

CLL

November 10, 2021

DLBCL

Greg Nowakowski, MD
Mayo Clinic, Rochester, Minnesota

December 8, 2021

MZL​

Leo Gordon, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

January 12, 2022

Updates from ASH 2021​

February 9, 2022

Follicular Lymphoma​

Carla Casulo, MD
University of Rochester Medical Center, Rochester, New York

March 9, 2022

Series Review​

John Leonard, MD
Weill Cornell Medicine

Recordings From Previous Webinars

Updates from ASH and Year in Review

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast on January 13, 2021

Follicular Lymphoma

Jonathon Cohen, MD, MS
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast on December 9, 2020

Marginal Zone Lymphoma

Peter Martin, MD
Weill Cornell Medicine | New York, New York
Broadcast on November 11, 2020

T-cell Lymphoma

Kerry Savage, MD
University of British Columbia | Vancouver, Canada
Broadcast on October 14, 2020

Hodgkin Lymphoma

Jonathan Friedberg, MD, MMSc
University of Rochester Medical Center | Rochester, New York
Broadcast on September 9, 2020

Updates from ASCO and EHA

John P. Leonard, MD
Weill Cornell Medical College | New York, New York
Broadcast on August 12, 2020

Chronic Lymphocytic Leukemia

Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on July 8, 2020

Transformed Lymphoma

Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center | New York, New York
Broadcast on June 10, 2020

Diffuse Large B-cell Lymphoma

Mitchell Smith, MD, PhD
George Washington University | Washington, District of Columbia
Broadcast on May 13, 2020

CAR T-Cell Therapy

Julie Vose, MD, MBA
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on April 8, 2020

Mantle Cell Lymphoma

Thomas Witzig, MD
Mayo Clinic | Rochester, Minnesota
Broadcast on March 11, 2020

Updates from ASH

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast on February 19, 2020

Target Audience
The target audience for this activity is clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
Learning Objectives
After completing this activity, participants should be better able to:
  • Assess best available evidence regarding treatment of indolent and aggressive B-cell lymphomas
  • Evaluate the clinical implications of emerging data regarding B-cell lymphoma treatment approaches
  • Plan strategies to address complicated B-cell lymphoma cases
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Disclosure Statement
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Contact Us

Questions? Please contact Bio Ascend by phone: 888-476-9129 or email: info@bioascend.com!

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.